Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIELO phase 3 trial of satralizumab in anti-NMDAR or anti-LGI1 autoimmune encephalitis
MOH_2025-06-04_014124Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autoimmune Encephalitis (AE), anti-NMDA receptor encephalitis and Anti-leucine-rich glioma inactivated 1 encephalitis comparing Satralizumab with Placebo (2 arms). Primary endpoint: Primary endpoint not reported in registry entry. Planned start May 2025; status: not yet recruiting.
02
Drugs
satralizumab
03
Conditions
Autoimmune Encephalitis (AE)anti-NMDA receptor encephalitisAnti-leucine-rich glioma inactivated 1 encephalitis
Beyond the preview
Go deeper on MOH_2025-06-04_014124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-04_014124.